share_log

Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65

Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65

Canaccord Genuity 维持对 CervoMed 的买入,将目标股价上调至 65 美元
Benzinga ·  04/08 07:37

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 to $65.

Canaccord Genuity分析师苏曼特·库尔卡尼维持CervoMED(纳斯达克股票代码:CRVO)的买入并将目标股价从50美元上调至65美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发